keyword
Keywords Philadelphia positive Acute ly...

Philadelphia positive Acute lymphoblastic leukemia

https://read.qxmd.com/read/38222242/ponatinib-improved-the-prognosis-of-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-a-japanese-single-center-cohort-study
#21
JOURNAL ARTICLE
Nagi Tozawa, Takaya Yamashita, Miho Nara, Yuki Fujioka, Sho Ikeda, Takahiro Kobayashi, Isuzu Kobayashi, Akihiro Kitadate, Yoshihiro Kameoka, Naoto Takahashi
Introduction The overall survival (OS) of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) has improved with the combination of tyrosine kinase inhibitor (TKI) with intensive chemotherapy. In recent years, there has been increased interest in the possibility of long-term survival without allogeneic hematopoietic stem cell transplantation (HSCT) or maintenance therapy. The aim of this study was to determine the effectiveness of treatment and the resultant outcomes in Ph+ALL patients using real-world data...
December 2023: Curēus
https://read.qxmd.com/read/38212207/dose-dense-mini-hyper-cvd-inotuzumab-ozogamicin-and-blinatumomab-achieves-rapid-mrd-negativity-in-philadelphia-chromosome-negative-b-cell-acute-lymphoblastic-leukemia
#22
JOURNAL ARTICLE
Nicholas J Short, Elias Jabbour, Trevor Jamison, Shilpa Paul, Branko Cuglievan, David McCall, Amber Gibson, Nitin Jain, Fadi G Haddad, Lewis F Nasr, Kayleigh R Marx, Caitlin Rausch, J Michael Savoy, Rebecca Garris, Farhad Ravandi, Hagop Kantarjian
BACKGROUND: The combination of low-intensity chemotherapy and inotuzumab ozogamicin (INO), with sequential blinatumomab, is highly effective in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) and in relapsed or refractory B-cell ALL. Earlier, "dose-dense" administration of blinatumomab could lead to earlier and deeper measurable residual disease (MRD) responses and better outcomes. PATIENTS AND METHODS: We performed a retrospective analysis of the safety and efficacy of a dose-dense regimen of mini-hyper-CVD (mini-hyperfractionated cyclophosphamide, vincristine, and dexamethasone alternating with mini-methotrexate and cytarabine), INO, and blinatumomab in patients with B-cell ALL...
December 30, 2023: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38185587/soho-state-of-the-art-updates-and-next-questions-update-on-the-approach-to-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia
#23
REVIEW
Fadi G Haddad, Elias Jabbour, Nicholas J Short, Nitin Jain, Hagop Kantarjian
The outcome of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) has improved significantly following the introduction of the BCR::ABL1 tyrosine kinase inhibitors (TKIs). The addition of newer-generation and more potent TKIs resulted in higher rates of molecular responses and better survival. Achieving a complete molecular remission (CMR; disappearance of the BCR::ABL1 transcripts) within the first 3 months of therapy is an important endpoint in newly diagnosed Ph-positive ALL that identifies patients who have an excellent long-term survival and who may not need to receive an allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission (CR)...
December 14, 2023: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38173667/percutaneous-perirenal-mass-biopsy-in-a-sitting-position-revealed-extramedullary-relapse-of-acute-lymphoblastic-leukemia
#24
JOURNAL ARTICLE
Yuki Oba, Ryo Koizumi, Kosei Kageyama, Masatoshi Yoshimoto, Shigekazu Kurihara, Daisuke Ikuma, Kyosuke Yamaguchi, Masayuki Yamanouchi, Tatsuya Suwabe, Kazuya Ishiwata, Atsushi Wake, Yoshifumi Ubara, Naoki Sawa
BACKGROUND/AIM: Acute lymphoblastic leukemia (ALL) is a blood malignancy characterized by a rapid proliferation of lymphoid progenitor cells. Extramedullary relapse (EMR) is the recurrence of leukemia that occurs outside the bone marrow. The central nervous system is the most prevalent site of EMR in ALL, whereas other organs, particularly the renal organs, are less commonly involved. CASE REPORT: A 49-year-old man diagnosed with Philadelphia chromosome-negative ALL (Ph-negative ALL) received a second umbilical cord blood transplant (uCBT) and was confirmed to be in his third hematological complete remission...
2024: Cancer Diagn Progn
https://read.qxmd.com/read/38172124/targeting-il-17a-enhances-imatinib-efficacy-in-philadelphia-chromosome-positive-b-cell-acute-lymphoblastic-leukemia
#25
JOURNAL ARTICLE
Feng Wang, Yunxuan Li, Zhaona Yang, Wenbin Cao, Ying Liu, Luyao Zhao, Tingting Zhang, Chenxi Zhao, Jinmei Yu, Jiaojiao Yu, Jichao Zhou, Xiaowei Zhang, Ping-Ping Li, Mingzhe Han, Sizhou Feng, Billy Wai-Lung Ng, Zhuo-Wei Hu, Erlie Jiang, Ke Li, Bing Cui
Dysregulated hematopoietic niches remodeled by leukemia cells lead to imbalances in immunological mediators that support leukemogenesis and drug resistance. Targeting immune niches may ameliorate disease progression and tyrosine kinase inhibitor (TKI) resistance in Philadelphia chromosome-positive B-ALL (Ph+ B-ALL). Here, we show that T helper type 17 (Th17) cells and IL-17A expression are distinctively elevated in Ph+ B-ALL patients. IL-17A promotes the progression of Ph+ B-ALL. Mechanistically, IL-17A activates BCR-ABL, IL6/JAK/STAT3, and NF-kB signalling pathways in Ph+ B-ALL cells, resulting in robust cell proliferation and survival...
January 3, 2024: Nature Communications
https://read.qxmd.com/read/38146355/association-of-cdkn2a-2b-deletion-with-relapse-after-hematopoietic-stem-cell-transplantation-for-acute-lymphoblastic-leukemia
#26
JOURNAL ARTICLE
Makoto Onizuka, Eri Kikkawa, Shinichiro Machida, Masako Toyosaki, Rikio Suzuki, Daisuke Ogiya, Yasuyuki Aoyama, Jun Amaki, Kaito Harada, Ryujiro Hara, Sawako Shiraiwa, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando
The most important prognostic factor for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) is minimal residual disease (MRD). Previous studies have reported copy number variants of genes such as IKZF1 , CDKN2A/2B , and PAX5 . These gene mutations can be analyzed using multiplex ligation-dependent probe amplification (MLPA), which is less costly and easier to perform than large-scale gene mutation analyses. In this study, we performed copy number variant analysis of leukemia cells at the first onset of Ph+ALL in a case series of allogeneic hematopoietic stem cell transplantation (allo-HSCT) using the MLPA method...
August 25, 2023: Blood Cell Ther
https://read.qxmd.com/read/38143593/bi-lineage-b-and-t-lymphoid-extramedullary-blast-crisis-at-an-initial-presentation-of-chronic-myeloid-leukemia-a-case-report-and-literature-review-of-extramedullary-blast-crisis
#27
Naoufal Benlachgar, Azlarab Masrar, Soukaina Haidouri, Hicham Harmouche, Zoubida Tazi Mezalek
Chronic myeloid leukemia (CML) with BCR-ABL1-positive cells is a myeloproliferative neoplasm (MPN) characterized by a chromosomal translocation t(9,22)(q34.1;q11.2), which results in the formation of a Philadelphia (Ph) chromosome containing the BCR-ABL1 fusion gene. Extramedullary blast crisis (EBC) associated with bcr/abl-positive CML is a rare initial presentation. Here, we present and discuss the case of a 51-year-old man who presented with a weight loss history, cervical swelling, and left-sided abdominal pain...
November 2023: Curēus
https://read.qxmd.com/read/38136329/how-to-manage-philadelphia-positive-acute-lymphoblastic-leukemia-in-resource-constrained-settings
#28
REVIEW
Wellington Silva, Eduardo Rego
Recent studies have indicated that more than half of adult patients newly diagnosed with Ph+ ALL can now achieve a cure. However, determining the most suitable protocol for less-resourced settings can be challenging. In these situations, we must consider the potential for treatment toxicity and limited access to newer agents and alloSCT facilities. Currently, it is advisable to use less intensive induction regimens for Ph+ ALL. These regimens can achieve high rates of complete remission while causing fewer induction deaths...
December 10, 2023: Cancers
https://read.qxmd.com/read/38132276/low-intensity-and-chemo-free-treatments-in-ph-all-progression-free-survival-based-on-indirect-comparisons
#29
REVIEW
Melania Rivano, Daniele Mengato, Marco Chiumente, Andrea Messori
In Philadelphia chromosome-positive B-cell (Ph+) acute lymphoblastic leukemia (LLA), growing evidence has accumulated regarding the efficacy of low-intensity and chemo-free regimens. Our objective was to analyze all recent trials evaluating these treatments and to compare them in terms of efficacy. We applied the Shiny method, an artificial intelligence technique, to analyze Kaplan-Meier curves and reconstruct patient-level data. Reconstructed patient data were then evaluated through standard survival statistics and subjected to indirect head-to-head treatment comparisons...
November 26, 2023: Hematology Reports
https://read.qxmd.com/read/38114052/harmonizing-the-craft-of-crafting-clinically-endorsed-small-molecule-bcr-abl-tyrosine-kinase-inhibitors-for-the-treatment-of-hematological-malignancies
#30
REVIEW
Lu Sun, Peng-Cheng Yang, Li Luan, Jin-Feng Sun, Ya-Tao Wang
The advancement and practical use of small-molecule tyrosine kinase inhibitors (TKIs) that specifically target the BCR-ABL fusion protein have introduced a revolutionary era of precision medicine for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This review offers a comprehensive exploration of the synthesis, mechanisms of action, and clinical implementation of clinically validated TKIs in the context of BCR-ABL, emphasizing the remarkable strides made in achieving therapeutic precision...
December 17, 2023: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/38107158/case-report-of-renal-calculi-in-a-child-receiving-imatinib-for-acute-lymphoblastic-leukemia
#31
Alaa Bamahmud, Mohamed El-Sherbiny, Roman Jednak, Karl Muchantef, Sharon Abish, David Mitchell, Catherine Vezina, Indra R Gupta
RATIONALE: Imatinib is used in the treatment of Philadelphia chromosome positive (Ph+) leukemias and has been reported to have a direct effect on bone physiology. PRESENTATION: To report on a child with Ph+ acute lymphoblastic leukemia who presented with bilateral flank pain and gross hematuria. DIAGNOSIS: She was diagnosed with obstructive kidney stones 101 days after commencing daily oral imatinib. Stone analysis revealed the presence of calcium phosphate...
2023: Canadian Journal of Kidney Health and Disease
https://read.qxmd.com/read/38107066/treatment-for-a-primary-multidrug-resistant-b-cell-acute-lymphoblastic-leukemia-patient-carrying-a-ssbp2-csf1r-fusion-gene-a-case-report
#32
Huan Wang, Yujiao Wang, Liangchun Hao, Xuan Liu, Jihong Zhang, Pin Yao, Danping Liu, Runan Wang
SSBP2-CSF1R is an important biomarker for clinical diagnosis and prognosis of Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL). This case report presents a pediatric Ph-like ALL patient carrying the SSBP2-CSF1R fusion gene. The patient was resistant to most conventional chemotherapy regimens and to dasatinib, an inhibitor that has been reported to have a therapeutic effect on SSBP2-CSF1R fusion Ph-like ALL, as she remained minimal residual disease (MRD) positive (detection by flow cytometry) and SSBP2-CSF1R fusion gene (detection by RT-PCR) positive after five rounds of such regimens...
2023: Frontiers in Oncology
https://read.qxmd.com/read/38066875/leveraging-health-care-technology-to-improve-health-outcomes-and-reduce-outcome-disparities-in-aya-leukemia
#33
JOURNAL ARTICLE
John C Molina, Seth Rotz
Significant improvements have occurred for adolescent and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients following the widespread adoption of "pediatric-inspired" treatment regimens for AYA patients cared for in adult oncology settings. However, for AYA patients, aged 15 to 39, an outcomes gap remains in B-ALL, necessitating the incorporation of novel therapies into up-front treatment regimens. As a result, clinical trial enrollment remains the current standard of care for AYA B-ALL across disease subtypes when available and accessible...
December 8, 2023: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/38035030/case-report-olverembatinib-monotherapy-the-chemotherapy-free-regimen-for-an-elderly-patient-with-relapsed-ph-positive-acute-lymphoblastic-leukemia
#34
Jianghua Ding, Wen Li
Background: The advent of first- and second-generation BCR/ABL1 tyrosine kinase inhibitors (TKIs), such as imatinib and dasatinib, has markedly improved the clinical outcomes of patients with philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ -ALL). However, due to acquired drug resistance, most Ph+ -ALL patients experience relapse. Thus, third-generation BCR/ABL1 TKIs, including ponatinib and olverembatinib, have been developed with the aim of overcoming drug resistance. Case report : A 79-year-old woman presented with intermittent fever and fatigue for 4 days...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/38031800/long-term-outcome-after-autologous-bcr-abl1-negative-peripheral-blood-stem-cell-transplantation-in-adults-with-philadelphia-positive-acute-lymphoblastic-leukemia-a-comparative-study
#35
JOURNAL ARTICLE
Leo Caillot, Mathieu Leclerc, Emmanuel Jacques Raphael Sleiman, Ivan Sloma, Orianne Wagner-Ballon, Alexis Claudel, Florence Beckerich, Rabah Redjoul, Christine Robin, Vincent Parinet, Cecile Pautas, Dehbia Menouche, Selwa Bouledroua, Ludovic Cabanne, Yakout Nait-Sidenas, Eric Gautier, Helene Rouard, Ingrid Lafon, Yves Chalandon, Nicolas Boissel, Denis Caillot, Sebastien Maury
Not available.
November 30, 2023: Haematologica
https://read.qxmd.com/read/38023231/case-report-deep-molecular-remissions-post-two-separate-cd19-targeted-chimeric-antigen-receptor-t-cell-therapies-do-not-prevent-disease-from-relapsing-in-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia
#36
Yu Tang, Xiaoming Fei, Xianqiu Yu, Jiang Cao, Lixia Wang, Fang Lei
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is an aggressive B-cell malignancy. The management of a relapsed Ph+ ALL patient is challenging. Currently, either allogeneic stem cell transplant (allo-SCT) or CD19-targeted chimeric antigen receptor T-cell (CAR T-cell) are usually employed as salvage modalities for a relapsed patient. However, there are few reports concerning cases that had both allo-SCT and multiple CAR T-cell therapies, and the optimal management of such patients is unclear...
2023: Frontiers in Oncology
https://read.qxmd.com/read/38014060/computational-modeling-of-stapled-coiled-coil-inhibitors-against-bcr-abl-toward-a-treatment-strategy-for-cml
#37
Maria Carolina P Lima, Braxten D Hornsby, Carol S Lim, Thomas E Cheatham
The chimeric oncoprotein Bcr-Abl is the causative agent of virtually all chronic myeloid leukemias (CML) and a subset of acute lymphoblastic leukemias (ALL). As a result of the so-called Philadelphia Chromosome translocation t(9;22), Bcr-Abl manifests as a constitutively active tyrosine kinase which promotes leukemogenesis by activation of cell cycle signaling pathways. Constitutive and oncogenic activation is mediated by an N-terminal coiled-coil oligomerization domain in Bcr (Bcr-CC), presenting a therapeutic target for inhibition of Bcr-Abl activity toward the treatment of Bcr-Abl+ leukemias...
November 17, 2023: bioRxiv
https://read.qxmd.com/read/38006571/reduced-intensity-allogenic-transplantation-for-children-and-adolescents-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia
#38
JOURNAL ARTICLE
Hisashi Ishida, Yuki Arakawa, Daiichiro Hasegawa, Ikuya Usami, Yoshiko Hashii, Yasuyuki Arai, Satoshi Nishiwaki, Dai Keino, Keisuke Kato, Maho Sato, Nao Yoshida, Yukiyasu Ozawa, Keiko Okada, Moe Hidaka, Yuki Yuza, Masatsugu Tanaka, Kenichiro Watanabe, Junko Takita, Yoshiyuki Kosaka, Naoto Fujita, Junji Tanaka, Atsushi Sato, Yoshiko Atsuta, Toshihiko Imamura
Survival rates of patients with Philadelphia chromosome-positive ALL (Ph+ALL) have improved considerably with the introduction of tyrosine kinase inhibitors (TKI); however, hematopoietic stem cell transplantation (HSCT) continues to play an important role. Reduced-intensity conditioning (RIC) regimens have been widely applied particularly for older patients, but their validity for children and adolescents with Ph+ALL has not been investigated. In this study, data from patients receiving HSCT for de novo Ph+ALL in first or second remission at ages younger than 25 years and with a history of pre-HSCT TKI therapy were retrospectively collected through the nationwide registry in Japan...
November 25, 2023: Annals of Hematology
https://read.qxmd.com/read/37986553/development-and-evaluation-of-a-rapid-one-step-high-sensitivity-real-time-quantitative-pcr-system-for-minor-bcr-abl-e1a2-test-in-philadelphia-positive-acute-lymphoblastic-leukemia-ph-all
#39
JOURNAL ARTICLE
Michihiro Hidaka, Koiti Inokuchi, Nobuhiko Uoshima, Naoto Takahashi, Nao Yoshida, Shuichi Ota, Hirohisa Nakamae, Hiromi Iwasaki, Kenichiro Watanabe, Yoshiyuki Kosaka, Norio Komatsu, Kuniaki Meguro, Yuho Najima, Tetsuya Eto, Takeshi Kondo, Shinya Kimura, Chikashi Yoshida, Yuichi Ishikawa, Masashi Sawa, Tomoko Hata, Keizo Horibe, Hiroatsu Iida, Takeshi Shimomura, Nobuaki Dobashi, Isamu Sugiura, Junya Makiyama, Naoyuki Miyagawa, Asuka Sato, Ryuta Ito, Itaru Matsumura, Yuzuru Kanakura, Tomoki Naoe
OBJECTIVE: Minimal residual disease assessment of BCR-ABL messenger ribonucleic acid levels is crucial in Philadelphia chromosome-positive acute lymphoblastic leukemia for prognosis and treatment planning. However, accurately quantifying minor BCR-ABL transcripts, which comprise 70% of Philadelphia chromosome-positive acute lymphoblastic leukemia cases, lacks a national-approved method. METHODS: We developed the "Otsuka" minor BCR-ABLmessenger ribonucleic acid assay kit with exceptional precision (0...
November 20, 2023: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/37940719/olverembatinib-combined-with-blinatumomab-in-treating-t315i-mutated-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-two-case-report
#40
JOURNAL ARTICLE
Shengxuan Fan, Lina Wang, Yaoyao Lu, Zijian Li
ABL tyrosine kinase inhibitors (TKIs) act an irreplaceable role in the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The treatment of these diseases has been revolutionized by the application of immunotherapeutic modalities. However, diseases with ABL kinase domain mutation T315I are resistant to the majority of TKIs, which is responsible for treatment failure. Olverembatinib is a third-generation TKI that has been approved for the treatment of T315I-mutated chronic myeloid leukemia (CML) in China; its usage in Ph+ ALL needs further exploration...
November 9, 2023: Annals of Hematology
keyword
keyword
74176
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.